In a report released today, Michael Matson from Needham maintained a Buy rating on Stryker (SYK – Research Report), with a price target of $442.00.
Michael Matson has given his Buy rating due to a combination of factors related to Stryker’s strategic acquisition of Inari Medical. Despite the immediate dilutive impact on Stryker’s operating margin and earnings per share (EPS) for 2025, the acquisition is expected to enhance the company’s gross margin and organic revenue growth in the long term.
Matson anticipates that the acquisition will contribute positively to Stryker’s financial performance by increasing its gross margin by approximately 70 basis points and boosting organic revenue growth by about 30 basis points after the first year. These anticipated benefits suggest a strong potential for future profitability and growth, justifying the Buy rating for Stryker’s stock.
According to TipRanks, Matson is an analyst with an average return of -7.2% and a 37.75% success rate. Matson covers the Healthcare sector, focusing on stocks such as Atricure, Boston Scientific, and Hologic.
In another report released on March 13, Jefferies also reiterated a Buy rating on the stock with a $465.00 price target.